Neurochemistry of schizophrenia: The contribution of neuroimaging postmortem pathology and neurochemistry in schizophrenia

Current Topics in Medicinal Chemistry

Volumn 12, Issue 21, 2012, Pages 2375-2392

  Dean, B ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Cannabinoid; Dopamine; Glutamate; Muscarinic; Neuroimaging; Schizophrenia; Serotonin

Indexed keywords

6 FLUORODOPAMINE F 18; AMPHETAMINE; BENZODIAZEPINE; DOPAMINE 1 RECEPTOR; DOPAMINE 2 RECEPTOR; DOPAMINE TRANSPORTER; DOXEPIN; METHAMPHETAMINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NEUROLEPTIC AGENT; NEUROTRANSMITTER; NEUROTRANSMITTER RECEPTOR; SEROTONIN;

BIPOLAR DISORDER; CAUDATE NUCLEUS; CENTRAL NERVOUS SYSTEM; GENE EXPRESSION; HUMAN; INFLAMMATION; NEUROCHEMISTRY; NEUROIMAGING; OUTCOME ASSESSMENT; PARKINSON DISEASE; PATHOPHYSIOLOGY; POSITRON EMISSION TOMOGRAPHY; PSYCHOSIS; REVIEW; SCHIZOPHRENIA; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

EID: 84874913750     PISSN: 15680266     EISSN: 18734294     Source Type: Journal    
DOI: 10.2174/156802612805289935     Document Type: Review

References (199)

1. Frost, J. J. Molecular imaging of the brain: a historical perspective Neuroimaging Clin.N.Am., 2003, 13, 653-658.
2. Agid, O.; Shapira, B.; Zislin, J.; Ritsner, M.; Hanin, B.; Murad, H.; Troudart, T.; Bloch, M.; Heresco-Levy, U.; Lerer, B. Environment and vulnerability to major psychiatric illness: a case control study of early parental loss in major depression, bipolar disorder and schizophrenia. Mol Psychiatry, 1999, 4, 163-172.
3. Tsuang, M. Schizophrenia: genes and environment. Biological Psychiatry, 2000, 47, 210-220.
4. Crow, T. J. Schizophrenia as the price that homo sapiens pays for language: a resolution of the central paradox in the origin of the species. Brain Res.Brain Res.Rev., 2000, 31, 118-129.
5. Dean, B. Is schizophrenia the price of human central nervous system complexity? Aust.N.Z.J.Psychiatry, 2009, 43, 13-24.
6. Harrison, P. J. Schizophrenia: a disorder of neurodevelopment? Curr.Opin.Neurobiol., 1997, 7, 285-289.
7. Meltzer, H. Y. Biological studies in schizophrenia. Schizophr.Bull., 1987, 13, 77-111.
8. Dean, B. Signal transmission, rather than reception, is the underlying neurochemical abnormality in schizophrenia. Aust.N.Z.J.Psychiatry, 2000, 34, 560-569.
9. Dean, B. The neurobiology of bipolar disorder: findings using human postmortem central nervous system tissue. Aust.N.Z.J.Psychiatry, 2004, 38, 135-140.
10. Carlsson, A. Does dopamine play a role in schizophrenia? Psychol.Med., 1977, 7, 583-597.
11. Sibley, D. R.; Monsma, F. J., Jr. Molecular biology of dopamine receptors. Trends Pharmacol.Sci., 1992, 13, 61-69.
12. Seeman, P.; Lee, T. Antipsychotic drugs: direct correlation between clinical potency and presynaptic action on dopamine neurons. Science, 1975, 188, 1217-1219.
13. Wong, D. F.; Wagner, H. N., Jr.; Tune, L. E.; Dannals, R. F.; Pearlson, G. D.; Links, J. M.; Tamminga, C. A.; Broussolle, E. P.; Ravert, H. T.; Wilson, A. A.; Toung, J. K.; Malat, J.; Williams, J. A.; O'Tuama, L. A.; Snyder, S. H.; Kuhar, M. J.; Gjedde, A. Positron emission tomography reveals elevated D2 dopamine receptors in drug-naive schizophrenics. Science, 1986, 234, 1558-1563.
14. Farde, L.; Wiesel, F. A.; Hall, H.; Halldin, C.; Stone-Elander, S.; Sedvall, G. No D2 receptor increase in PET study of schizophrenia. Arch.Gen.Psychiatry, 1987, 44, 671-672.
15. Martinot, J. L.; Huret, J. D.; Peron-Magnan, P.; Mazoyer, B. M.; Baron, J. C.; Caillard, V.; Syrota, A.; Loo, H. Striatal D2 dopaminergic receptor status ascertained in vivo by positron emission tomography and 76Br-bromospiperone in untreated schizophrenics. Psychiatry Research, 1989, 29, 357-358.
16. Tune, L. E.; Wong, D. F.; Pearlson, G.; Strauss, M.; Young, T.; Shaya, E. K.; Dannals, R. F.; Wilson, A. A.; Ravert, H. T.; Sapp, J.;. Dopamine D2 receptor density estimates in schizophrenia: a positron emission tomography study with 11C-N-methylspiperone. Psychiatry Research, 1993, 49, 219-237.
17. Tune, L.; Barta, P.; Wong, D.; Powers, R. E.; Pearlson, G.; Tien, A. Y.; Wagner, H. N. Striatal dopamine D2 receptor quantification and superior temporal gyrus: volume determination in 14 chronic schizophrenic subjects. Psychiatry Research, 1996, 67, 155-158.
18. Pearlson, G. D.; Wong, D. F.; Tune, L. E.; Ross, C. A.; Chase, G. A.; Links, J. M.; Dannals, R. F.; Wilson, A. A.; Ravert, H. T.; Wagner, H. N., Jr.;. In vivo D2 dopamine receptor density in psychotic and nonpsychotic patients with bipolar disorder. Arch.Gen.Psychiatry, 1995, 52, 471-477.
19. Wong, D. F.; Pearlson, G. D.; Tune, L. E.; Young, L. T.; Meltzer, C. C.; Dannals, R. F.; Ravert, H. T.; Reith, J.; Kuhar, M. J.; Gjedde, A. Quantification of neuroreceptors in the living human brain: IV. Effect of aging and elevations of D2-like receptors in schizophrenia and bipolar illness. J.Cereb.Blood Flow Metab, 1997, 17, 331-342.
20. Pearlson, G. D.; Tune, L. E.; Wong, D. F.; Aylward, E. H.; Barta, P. E.; Powers, R. E.; Tien, A. Y.; Chase, G. A.; Harris, G. J.; Rabins, P. V. Quantitative D2 dopamine receptor PET and structural MRI changes in late-onset schizophrenia. Schizophr.Bull., 1993, 19, 783-795.
21. Hietala, J.; Syvalahti, E.; Vuorio, K.; Nagren, K.; Lehikoinen, P.; Ruotsalainen, U.; Rakkolainen, V.; Lehtinen, V.; Wegelius, U. Striatal D2 dopamine receptor characteristics in neuroleptic-naive schizophrenic patients studied with positron emission tomography. Arch.Gen.Psychiatry, 1994, 51, 116-123.
22. Nordstrom, A. L.; Farde, L.; Eriksson, L.; Halldin, C. No elevated D2 dopamine receptors in neuroleptic-naive schizophrenic patients revealed by positron emission tomography and [11C]N- methylspiperone. Psychiatry Research, 1995, 61, 67-83.
23. Farde, L.; Wiesel, F. A.; Stone-Elander, S.; Halldin, C.; Nordstrom, A. L.; Hall, H.; Sedvall, G. D2 dopamine receptors in neuroleptic- naive schizophrenic patients. A positron emission tomography study with [11C]raclopride. Arch.Gen.Psychiatry, 1990, 47, 213-219.
24. Talvik, M.; Nordstrom, A. L.; Olsson, H.; Halldin, C.; Farde, L. Decreased thalamic D2/D3 receptor binding in drug-naive patients with schizophrenia: a PET study with [11C]FLB 457. Int.J.Neuropsychopharmacol., 2003, 6, 361-370.
25. Martinot, J. L.; Paillere-Martinot, M. L.; Loc'h, C.; Hardy, P.; Poirier, M. F.; Mazoyer, B.; Beaufils, B.; Maziere, B.; Allilaire, J. F.; Syrota, A. The estimated density of D2 striatal receptors in schizophrenia. A study with positron emission tomography and 76Br-bromolisuride. Br.J.Psychiatry, 1991, 158, 346-350.
26. Pilowsky, L. S.; Costa, D. C.; Ell, P. J.; Verhoeff, N. P.; Murray, R. M.; Kerwin, R. W. D2 dopamine receptor binding in the basal ganglia of antipsychotic-free schizophrenic patients. An 123I- IBZM single photon emission computerised tomography study. Br.J.Psychiatry, 1994, 164, 16-26.
27. Knable, M. B.; Egan, M. F.; Heinz, A.; Gorey, J.; Lee, K. S.; Coppola, R.; Weinberger, D. R. Altered dopaminergic function and negative symptoms in drug-free patients with schizophrenia. [123I]-iodobenzamide SPECT study. Br.J.Psychiatry, 1997, 171, 574-577.
28. Schroder, J.; Bubeck, B.; Silvestri, S.; Demisch, S.; Sauer, H. Gender differences in D2 dopamine receptor binding in drug-naive patients with schizophrenia: an [123I]iodobenzamide single photon emission computed tomography study. Psychiatry Research, 1997, 75, 115-123.
29. Lomena, F.; Catafau, A. M.; Parellada, E.; Bernardo, M.; Font, M.; Gutierrez, F.; Pavia, J. Striatal dopamine D2 receptor density in neuroleptic-naive and in neuroleptic-free schizophrenic patients: an 123I-IBZM-SPECT study. Psychophamacology (Berlin), 2004, 172, 165-169.
30. Parellada, E.; Lomena, F.; Catafau, A. M.; Bernardo, M.; Font, M.; Fernandez-Egea, E.; Pavia, J.; Gutierrez, F. Lack of sex differences in striatal dopamine D2 receptor binding in drug-naive schizophrenic patients: an IBZM-SPECT study. Psychiatry Research, 2004, 130, 79-84.
31. Bloemen, O. J.; de Koning, M. B.; Gleich, T.; Meijer, J.; de, H. L.; Linszen, D. H.; Booij, J.; van Amelsvoort, T. A. Striatal dopamine D(2/3) receptor binding following dopamine depletion in subjects at Ultra High Risk for psychosis. European Neuropsychopharmacology, 2012,
32. Seeman, P.; Niznik, H. B. Dopamine receptors and transporters in Parkinson's disease and schizophrenia. FASEB J., 1990, 4, 2737-2744.
33. Hess, E. J.; Bracha, H. S.; Kleinman, J. E.; Creese, I. Dopamine receptor subtype imbalance in schizophrenia. Life Sci., 1987, 40, 1487-1497.
34. Dean, B.; Pavey, G.; Opeskin, K. [3H]raclopride binding to brain tissue from subjects with schizophrenia: methodological aspects. Neuropharmacology, 1997, 36, 779-786.
35. Knable, M. B.; Hyde, T. M.; Herman, M. M.; Carter, J. M.; Bigelow, L.; Kleinman, J. E. Quantitative autoradiography of dopamine-D1 receptors, D2 receptors, and dopamine uptake sites in postmortem striatal specimens from schizophrenic patients. Biological Psychiatry, 1994, 36, 827-835.
36. Suhara, T.; Okubo, Y.; Yasuno, F.; Sudo, Y.; Inoue, M.; Ichimiya, T.; Nakashima, Y.; Nakayama, K.; Tanada, S.; Suzuki, K.; Halldin, C.; Farde, L. Decreased dopamine D2 receptor binding in the anterior cingulate cortex in schizophrenia. Arch.Gen.Psychiatry, 2002, 59, 25-30.
37. Tuppurainen, H.; Kuikka, J.; Viinamaki, H.; Husso-Saastamoinen, M.; Bergstrom, K.; Tiihonen, J. Extrastriatal dopamine D 2/3 receptor density and distribution in drug-naive schizophrenic patients. Mol.Psychiatry, 2003, 8, 453-455.
38. Meador-Woodruff, J. H.; Haroutunian, V.; Powchik, P.; Davidson, M.; Davis, K. L.; Watson, S. J. Dopamine receptor transcript expression in striatum and prefrontal and occipital cortex. Focal abnormalities in orbitofrontal cortex in schizophrenia. Arch.Gen.Psychiatry, 1997, 54, 1089-1095.
39. Zavitsanou, K.; Huang, X. F. Decreased [(3)H]spiperone binding in the anterior cingulate cortex of schizophrenia patients: an autoradiographic study. Neuroscience, 2002, 109, 709-716.
40. Dean, B.; Hussain, T.; Hayes, W.; Scarr, E.; Kitsoulis, S.; Hill, C.; Opeskin, K.; Copolov, D. L. Changes in serotonin2A and GABA(A) receptors in schizophrenia: studies on the human dorsolateral prefrontal cortex. J.Neurochem., 1999, 72, 1593-1599.
41. Buchsbaum, M. S.; Christian, B. T.; Lehrer, D. S.; Narayanan, T. K.; Shi, B.; Mantil, J.; Kemether, E.; Oakes, T. R.; Mukherjee, J. D2/D3 dopamine receptor binding with [F-18]fallypride in thalamus and cortex of patients with schizophrenia. Schizophr.Res., 2006, 85, 232-244.
42. Talvik, M.; Nordstrom, A. L.; Okubo, Y.; Olsson, H.; Borg, J.; Halldin, C.; Farde, L. Dopamine D2 receptor binding in drug-naive patients with schizophrenia examined with raclopride-C11 and positron emission tomography. Psychiatry Research, 2006, 148, 165-173.
43. Rinne, J. O.; Hietala, J.; Ruotsalainen, U.; Sako, E.; Laihinen, A.; Nagren, K.; Lehikoinen, P.; Oikonen, V.; Syvalahti, E. Decrease in human striatal dopamine D2 receptor density with age: a PET study with [11C]raclopride. J.Cereb.Blood Flow Metab, 1993, 13, 310-314.
44. Kaasinen, V.; Vilkman, H.; Hietala, J.; Nagren, K.; Helenius, H.; Olsson, H.; Farde, L.; Rinne, J. Age-related dopamine D2/D3 receptor loss in extrastriatal regions of the human brain. Neurobiol.Aging, 2000, 21, 683-688.
45. Seeman, P.; Bzowej, N. H.; Guan, H. C.; Bergeron, C.; Becker, L. E.; Reynolds, G. P.; Bird, E. D.; Riederer, P.; Jellinger, K.; Watanabe, S.;. Human brain dopamine receptors in children and aging adults. Synapse, 1987, 1, 399-404.
46. Dean, B.; Keriakous, D.; Scarr, E.; Thomas, E. A. Gene expression profiling in Brodmann's area 46 from subjects with schizophrenia. Aust.N.Z.J.Psychiatry, 2007, 41, 308-320.
47. Narayan, S.; Tang, B.; Head, S. R.; Gilmartin, T. J.; Sutcliffe, J. G.; Dean, B.; Thomas, E. A. Molecular profiles of schizophrenia in the CNS at different stages of illness. Brain Res., 2008, 1239, 235-248.
48. Tang, B.; Chang, W. L.; Lanigan, C. M.; Dean, B.; Sutcliffe, J. G.; Thomas, E. A. Normal human aging and early-stage schizophrenia share common molecular profiles. Aging Cell, 2009, 8, 339-342.
49. Kebabian, J. W.; Calne, D. B. Multiple receptors for dopamine. Nature, 1979, 277, 93-96.
50. Hall, H.; Sedvall, G.; Magnusson, O.; Kopp, J.; Halldin, C.; Farde, L. Distribution of D1- and D2-dopamine receptors, and dopamine and its metabolites in the human brain. Neuropsychopharmacology, 1994, 11, 245-256.
51. Okubo, Y.; Suhara, T.; Suzuki, K.; Kobayashi, K.; Inoue, O.; Terasaki, O.; Someya, Y.; Sassa, T.; Sudo, Y.; Matsushima, E.; Iyo, M.; Tateno, Y.; Toru, M. Decreased prefrontal dopamine D1 receptors in schizophrenia revealed by PET. Nature, 1997, 385, 634-636.
52. Kosaka, J.; Takahashi, H.; Ito, H.; Takano, A.; Fujimura, Y.; Matsumoto, R.; Nozaki, S.; Yasuno, F.; Okubo, Y.; Kishimoto, T.; Suhara, T. Decreased binding of [11C]NNC112 and [11C]SCH23390 in patients with chronic schizophrenia. Life Sci., 2010, 86, 814-818.
53. Abi-Dargham, A.; Xu, X.; Thompson, J. L.; Gil, R.; Kegeles, L. S.; Urban, N. B.; Narendran, R.; Hwang, D. R.; Laruelle, M.; Slifstein, M. Increased prefrontal cortical D1 receptors in drug naive patients with schizophrenia: a PET study with [11C]NNC112. J.Psychopharmacol., 2011,
54. Abi-Dargham, A.; Mawlawi, O.; Lombardo, I.; Gil, R.; Martinez, D.; Huang, Y.; Hwang, D. R.; Keilp, J.; Kochan, L.; Van Heertum, R.; Gorman, J. M.; Laruelle, M. Prefrontal dopamine D1 receptors and working memory in schizophrenia. J.Neurosci., 2002, 22, 3708-3719.
55. Karlsson, P.; Farde, L.; Halldin, C.; Sedvall, G. PET study of D(1) dopamine receptor binding in neuroleptic-naive patients with schizophrenia. Am.J.Psychiatry, 2002, 159, 761-767.
56. Pimoule, C.; Schoemaker, H.; Reynolds, G. P.; Langer, S. Z. [3H]SCH 23390 labeled D1 dopamine receptors are unchanged in schizophrenia and Parkinson's disease. Eur.J.Pharmacol., 1985, 114, 235-237.
57. Seeman, P.; Bzowej, N. H.; Guan, H. C.; Bergeron, C.; Reynolds, G. P.; Bird, E. D.; Riederer, P.; Jellinger, K.; Tourtellotte, W. W. Human brain D1 and D2 dopamine receptors in schizophrenia, Alzheimer's, Parkinson's, and Huntington's diseases. Neuropsychopharmacology, 1987, 1, 5-15.
58. Knable, M. B.; Hyde, T. M.; Murray, A. M.; Herman, M. M.; Kleinman, J. E. A postmortem study of frontal cortical dopamine D1 receptors in schizophrenics, psychiatric controls, and normal controls. Biological Psychiatry, 1996, 40, 1191-1199.
59. Domyo, T.; Kurumaji, A.; Toru, M. An increase in [3H]SCH23390 binding in the cerebral cortex of postmortem brains of chronic schizophrenics. J.Neural Transm., 2001, 108, 1475-1484.
60. Buckland, P. R.; O'Donovan, M. C.; McGuffin, P. Changes in dopamine D1, D2 and D3 receptor mRNA levels in rat brain following antipsychotic treatment. Psychophamacology (Berlin), 1992, 106, 479-483.
61. D'Souza, U.; McGuffin, P.; Buckland, P. R. Antipsychotic regulation of dopamine D1, D2 and D3 receptor mRNA. Neuropharmacology, 1997, 36, 1689-1696.
62. Lidow, M. S.; Elsworth, J. D.; Goldman-Rakic, P. S. Down- regulation of the D1 and D5 dopamine receptors in the primate prefrontal cortex by chronic treatment with antipsychotic drugs. J.Pharmacol.Exp.Ther., 1997, 281, 597-603.
63. Dean, B.; Hussain, T.; Scarr, E.; Pavey, G.; Copolov, D. L. Extended treatment with typical and atypical antipsychotic drugs differential effects on the densities of dopamine D2-like and GABAA receptors in rat striatum. Life Sci., 2001, 69, 1257-1268.
64. Giros, B.; Jaber, M.; Jones, S. R.; Wightman, R. M.; Caron, M. G. Hyperlocomotion and indifference to cocaine and amphetamine in mice lacking the dopamine transporter. Nature, 1996, 379, 606-612.
65. Laakso, A.; Vilkman, H.; Alakare, B.; Haaparanta, M.; Bergman, J.; Solin, O.; Peurasaari, J.; Rakkolainen, V.; Syvalahti, E.; Hiet-aletal/et-ala, J. Striatal dopamine transporter binding in neuroleptic-naive patients with schizophrenia studied with positron emission tomography. Am.J.Psychiatry, 2000, 157, 269-271.
66. Laruelle, M.; Abi-Dargham, A.; van Dyck, C.; Gil, R.; D'Souza, D. C.; Krystal, J.; Seibyl, J.; Baldwin, R.; Innis, R. Dopamine and serotonin transporters in patients with schizophrenia: an imaging study with [(123)I]beta-CIT. Biological Psychiatry, 2000, 47, 371-379.
67. Hsiao, M. C.; Lin, K. J.; Liu, C. Y.; Tzen, K. Y.; Yen, T. C. Dopamine transporter change in drug-naive schizophrenia: an imaging study with 99mTc-TRODAT-1. Schizophr.Res., 2003, 65, 39-46.
68. Yang, Y. K.; Yu, L.; Yeh, T. L.; Chiu, N. T.; Chen, P. S.; Lee, I. H. Associated alterations of striatal dopamine D2/D3 receptor and transporter binding in drug-naive patients with schizophrenia: a dual-isotope SPECT study. Am.J.Psychiatry, 2004, 161, 1496-1498.
69. Schmitt, G. J.; Meisenzahl, E. M.; Frodl, T.; La, F. C.; Hahn, K.; Moller, H. J.; Dresel, S. The striatal dopamine transporter in first-episode, drug-naive schizophrenic patients: evaluation by the new SPECT-ligand[99mTc]TRODAT-1. J.Psychopharmacol., 2005, 19, 488-493.
70. Schmitt, G. J.; Frodl, T.; Dresel, S.; La, F. C.; Bottlender, R.; Koutsouleris, N.; Hahn, K.; Moller, H. J.; Meisenzahl, E. M. Striatal dopamine transporter availability is associated with the productive psychotic state in first episode, drug-naive schizophrenic patients. Eur.Arch.Psychiatry Clin.Neurosci., 2006, 256, 115-121.
71. Schmitt, G. J.; La, F. C.; Dresel, S.; Frodl, T.; Hahn, K.; Moller, H. J.; Meisenzahl, E. M. Dual-isotope SPECT imaging of striatal dopamine: first episode, drug naive schizophrenic patients. Schizophr.Res., 2008, 101, 133-141.
72. Arakawa, R.; Ichimiya, T.; Ito, H.; Takano, A.; Okumura, M.; Takahashi, H.; Takano, H.; Yasuno, F.; Kato, M.; Okubo, Y.; Suhara, T. Increase in thalamic binding of [(11)C]PE2I in patients with schizophrenia: a positron emission tomography study of dopamine transporter. J.Psychiatr.Res., 2009, 43, 1219-1223.
73. Laakso, A.; Bergman, J.; Haaparanta, M.; Vilkman, H.; Solin, O.; Syvalahti, E.; Hiet-aletal/et-ala, J. Decreased striatal dopamine transporter binding in vivo in chronic schizophrenia. Schizophr.Res., 2001, 52, 115-120.
74. Mateos, J. J.; Lomena, F.; Parellada, E.; Font, M.; Fernandez, E.; Pavia, J.; Prats, A.; Pons, F.; Bernardo, M. Decreased striatal dopamine transporter binding assessed with [123I] FP-CIT in first- episode schizophrenic patients with and without short-term antipsychotic-induced parkinsonism. Psychophamacology (Berlin), 2005, 181, 401-406.
75. Mateos, J. J.; Lomena, F.; Parellada, E.; Mireia, F.; Fernandez- Egea, E.; Pavia, J.; Prats, A.; Pons, F.; Bernardo, M. Lower striatal dopamine transporter binding in neuroleptic-naive schizophrenic patients is not related to antipsychotic treatment but it suggests an illness trait. Psychophamacology (Berlin), 2007, 191, 805-811.
76. Sjoholm, H.; Bratlid, T.; Sundsfjord, J. 123I-beta-CIT SPECT demonstrates increased presynaptic dopamine transporter binding sites in basal ganglia in vivo in schizophrenia. Psychophamacology (Berlin), 2004, 173, 27-31.
77. Pearce, R. K.; Seeman, P.; Jellinger, K.; Tourtellotte, W. W. Dopamine uptake sites and dopamine receptors in Parkinson's disease and schizophrenia. Eur.Neurol., 1990, 30 Suppl 1, 9-14.
78. Hitri, A.; Casanova, M. F.; Kleinman, J. E.; Weinberger, D. R.; Wyatt, R. J. Age-related changes in [3H]GBR 12935 binding site density in the prefrontal cortex of controls and schizophrenics. Biological Psychiatry, 1995, 37, 175-182.
79. Dean, B.; Hussain, T. Studies on dopaminergic and GABAergic markers in striatum reveals a decrease in the dopamine transporter in schizophrenia. Schizophr.Res., 2001, 52, 107-114.
80. Tarazi, F. I.; Zhang, K.; Baldessarini, R. J. Olanzapine, quetiapine, and risperidone: long-term effects on monoamine transporters in rat forebrain. Neurosci.Lett., 2000, 287, 81-84.
81. Hietala, J.; Syvalahti, E.; Vuorio, K.; Rakkolainen, V.; Bergman, J.; Haaparanta, M.; Solin, O.; Kuoppamaki, M.; Kirvela, O.; Ruotsalainen, U.;. Presynaptic dopamine function in striatum of neuroleptic-naive schizophrenic patients. Lancet, 1995, 346, 1130-1131.
82. Laruelle, M.; Abi-Dargham, A.; van Dyck, C. H.; Gil, R.; D'Souza, C. D.; Erdos, J.; McCance, E.; Rosenblatt, W.; Fingado, C.; Zoghbi, S. S.; Baldwin, R. M.; Seibyl, J. P.; Krystal, J. H.; Charney, D. S.; Innis, R. B. Single photon emission computerized tomography imaging of amphetamine-induced dopamine release in drug-free schizophrenic subjects. Proc.Natl.Acad.Sci.U.S.A, 1996, 93, 9235-9240.
83. Hietala, J.; Syvalahti, E.; Vilkman, H.; Vuorio, K.; Rakkolainen, V.; Bergman, J.; Haaparanta, M.; Solin, O.; Kuoppamaki, M.; Eronen, E.; Ruotsalainen, U.; Salokangas, R. K. Depressive symptoms and presynaptic dopamine function in neuroleptic-naive schizophrenia. Schizophr.Res., 1999, 35, 41-50.
84. Elkashef, A. M.; Doudet, D.; Bryant, T.; Cohen, R. M.; Li, S. H.; Wyatt, R. J. 6-(18)F-DOPA PET study in patients with schizophrenia. Positron emission tomography. Psychiatry Research, 2000, 100, 1-11.
85. Kumakura, Y.; Cumming, P.; Vernaleken, I.; Buchholz, H. G.; Siessmeier, T.; Heinz, A.; Kienast, T.; Bartenstein, P.; Grunder, G. Elevated [18F]fluorodopamine turnover in brain of patients with schizophrenia: an [18F]fluorodopa/positron emission tomography study. J.Neurosci., 2007, 27, 8080-8087.
86. Bose, S. K.; Turkheimer, F. E.; Howes, O. D.; Mehta, M. A.; Cunliffe, R.; Stokes, P. R.; Grasby, P. M. Classification of schizophrenic patients and healthy controls using [18F] fluorodopa PET imaging. Schizophr.Res., 2008, 106, 148-155.
87. Abi-Dargham, A.; van de Giessen, E.; Slifstein, M.; Kegeles, L. S.; Laruelle, M. Baseline and amphetamine-stimulated dopamine activity are related in drug-naive schizophrenic subjects. Biological Psychiatry, 2009, 65, 1091-1093.
88. Abi-Dargham, A.; Gil, R.; Krystal, J.; Baldwin, R. M.; Seibyl, J. P.; Bowers, M.; van Dyck, C. H.; Charney, D. S.; Innis, R. B.; Laruelle, M. Increased striatal dopamine transmission in schizophrenia: confirmation in a second cohort. Am.J.Psychiatry, 1998, 155, 761-767.
89. Breier, A.; Su, T. P.; Saunders, R.; Carson, R. E.; Kolachana, B. S.; de Bartolomeis, A.; Weinberger, D. R.; Weisenfeld, N.; Malhotra, A. K.; Eckelman, W. C.; Pickar, D. Schizophrenia is associated with elevated amphetamine-induced synaptic dopamine concentrations: evidence from a novel positron emission tomography method. Proc.Natl.Acad.Sci.U.S.A, 1997, 94, 2569-2574.
90. Abi-Dargham, A.; Kegeles, L. S.; Zea-Ponce, Y.; Mawlawi, O.; Martinez, D.; Mitropoulou, V.; O'Flynn, K.; Koenigsberg, H. W.; Van, H. R.; Cooper, T.; Laruelle, M.; Siever, L. J. Striatal amphetamine-induced dopamine release in patients with schizotypal personality disorder studied with single photon emission computed tomography and [123I]iodobenzamide. Biological Psychiatry, 2004, 55, 1001-1006.
91. Volkow, N. D.; Chang, L.; Wang, G. J.; Fowler, J. S.; Ding, Y. S.; Sedler, M.; Logan, J.; Franceschi, D.; Gatley, J.; Hitzemann, R.; Gifford, A.; Wong, C.; Pappas, N. Low level of brain dopamine D2 receptors in methamphetamine abusers: association with metabolism in the orbitofrontal cortex. Am.J.Psychiatry, 2001, 158, 2015-2021.
92. Sekine, Y.; Iyo, M.; Ouchi, Y.; Matsunaga, T.; Tsukada, H.; Okada, H.; Yoshikawa, E.; Futatsubashi, M.; Takei, N.; Mori, N. Methamphetamine-related psychiatric symptoms and reduced brain dopamine transporters studied with PET. Am.J.Psychiatry, 2001, 158, 1206-1214.
93. Barr, A. M.; Panenka, W. J.; MacEwan, G. W.; Thornton, A. E.; Lang, D. J.; Honer, W. G.; Lecomte, T. The need for speed: an update on methamphetamine addiction. J.Psychiatry Neurosci., 2006, 31, 301-313.
94. Gibb, W. R.; Lees, A. J. Anatomy, pigmentation, ventral and dorsal subpopulations of the substantia nigra, and differential cell death in Parkinson's disease. J.Neurol.Neurosurg.Psychiatry, 1991, 54, 388-396.
95. Rinne, U. K.; Laihinen, A.; Rinne, J. O.; Nagren, K.; Bergman, J.; Ruotsalainen, U. Positron emission tomography demonstrates dopamine D2 receptor supersensitivity in the striatum of patients with early Parkinson's disease. Mov Disord., 1990, 5, 55-59.
96. Kaasinen, V.; Ruottinen, H. M.; Nagren, K.; Lehikoinen, P.; Oikonen, V.; Rinne, J. O. Upregulation of putaminal dopamine D2 receptors in early Parkinson's disease: a comparative PET study with [11C] raclopride and [11C]N-methylspiperone. J.Nucl.Med., 2000, 41, 65-70.
97. Bartlett, S. E.; Enquist, J.; Hopf, F. W.; Lee, J. H.; Gladher, F.; Kharazia, V.; Waldhoer, M.; Mailliard, W. S.; Armstrong, R.; Bonci, A.; Whistler, J. L. Dopamine responsiveness is regulated by targeted sorting of D2 receptors. Proc.Natl.Acad.Sci.U.S.A, 2005, 102, 11521-11526.
98. Breier, A. Serotonin, schizophrenia and antipsychotic drug action. Schizophr.Res., 1995, 14, 187-202.
99. Peroutka, S. J.; Snyder, S. H. Multiple serotonin receptors: differential binding of [3H]5-hydroxytryptamine, [3H]lysergic acid diethylamide and [3H]spiroperidol. Mol Pharmacol., 1979, 16, 687-699.
100. Baumeister, A. A.; Hawkins, M. F. The serotonin hypothesis of schizophrenia: a historical case study on the heuristic value of theory in clinical neuroscience. J.Hist Neurosci., 2004, 13, 277-291.
101. Meltzer, H. Y. The importance of serotonin-dopamine interactions in the action of clozapine. Br.J.Psychiatry Suppl, 1992, 22-29.
102. Dean, B. The cortical serotonin2A receptor and the pathology of schizophrenia: a likely accomplice. J.Neurochem., 2003, 85, 1-13.
103. Trichard, C.; Paillere-Martinot, M. L.; Attar-Levy, D.; Blin, J.; Feline, A.; Martinot, J. L. No serotonin 5-HT2A receptor density abnormality in the cortex of schizophrenic patients studied with PET. Schizophr.Res., 1998, 31, 13-17.
104. Lewis, R.; Kapur, S.; Jones, C.; DaSilva, J.; Brown, G. M.; Wilson, A. A.; Houle, S.; Zipursky, R. B. Serotonin 5-HT2 receptors in schizophrenia: a PET study using [18F]setoperone in neuroleptic- naive patients and normal subjects. Am.J.Psychiatry, 1999, 156, 72-78.
105. Okubo, Y.; Suhara, T.; Suzuki, K.; Kobayashi, K.; Inoue, O.; Terasaki, O.; Someya, Y.; Sassa, T.; Sudo, Y.; Matsushima, E.; Iyo, M.; Tateno, Y.; Toru, M. Serotonin 5-HT2 receptors in schizophrenic patients studied by positron emission tomography. Life Sci., 2000, 66, 2455-2464.
106. Verhoeff, N. P.; Meyer, J. H.; Kecojevic, A.; Hussey, D.; Lewis, R.; Tauscher, J.; Zipursky, R. B.; Kapur, S. A voxel-by-voxel analysis of [18F]setoperone PET data shows no substantial serotonin 5-HT(2A) receptor changes in schizophrenia. Psychiatry Research, 2000, 99, 123-135.
107. Ngan, E. T.; Yatham, L. N.; Ruth, T. J.; Liddle, P. F. Decreased serotonin 2A receptor densities in neuroleptic-naive patients with schizophrenia: A PET study using [(18)F]setoperone. Am.J.Psychiatry, 2000, 157, 1016-1018.
108. Hurlemann, R.; Matusch, A.; Kuhn, K. U.; Berning, J.; Elmenhorst, D.; Winz, O.; Kolsch, H.; Zilles, K.; Wagner, M.; Maier, W.; Bauer, A. 5-HT2A receptor density is decreased in the at-risk mental state. Psychophamacology (Berlin), 2008, 195, 579-590.
109. Hurlemann, R.; Boy, C.; Meyer, P. T.; Scherk, H.; Wagner, M.; Herzog, H.; Coenen, H. H.; Vogeley, K.; Falkai, P.; Zilles, K.; Maier, W.; Bauer, A. Decreased prefrontal 5-HT2A receptor binding in subjects at enhanced risk for schizophrenia. Anat.Embryol.(Berl), 2005, 210, 519-523.
110. Rasmussen, H.; Erritzoe, D.; Andersen, R.; Ebdrup, B. H.; Aggernaes, B.; Oranje, B.; Kalbitzer, J.; Madsen, J.; Pinborg, L. H.; Baare, W.; Svarer, C.; Lublin, H.; Knudsen, G. M.; Glenthoj, B. Decreased frontal serotonin2A receptor binding in antipsychotic- naivepatientswithfirst-episodeschizophrenia. Arch.Gen.Psychiatry, 2010, 67, 9-16.
111. Erritzoe, D.; Rasmussen, H.; Kristiansen, K. T.; Frokjaer, V. G.; Haugbol, S.; Pinborg, L.; Baare, W.; Svarer, C.; Madsen, J.; Lublin, H.; Knudsen, G. M.; Glenthoj, B. Y. Cortical and subcortical 5-HT2A receptor binding in neuroleptic-naive first- episode schizophrenic patients. Neuropsychopharmacology, 2008, 33, 2435-2441.
112. Nguyen, L.; Rigo, J. M.; Rocher, V.; Belachew, S.; Malgrange, B.; Rogister, B.; Leprince, P.; Moonen, G. Neurotransmitters as early signals for central nervous system development. Cell Tissue Res., 2001, 305, 187-202.
113. Lawrie, S. M.; Whalley, H. C.; Abukmeil, S. S.; Kestelman, J. N.; Donnelly, L.; Miller, P.; Best, J. J.; Owens, D. G.; Johnstone, E. C. Brain structure, genetic liability, and psychotic symptoms in subjects at high risk of developing schizophrenia. Biological Psychiatry, 2001, 49, 811-823.
114. Job, D. E.; Whalley, H. C.; McConnell, S.; Glabus, M.; Johnstone, E. C.; Lawrie, S. M. Voxel-based morphometry of grey matter densities in subjects at high risk of schizophrenia. Schizophr.Res., 2003, 64, 1-13.
115. Chan, R. C.; Di, X.; McAlonan, G. M.; Gong, Q. Y. Brain anatomical abnormalities in high-risk individuals, first-episode, and chronic schizophrenia: an activation likelihood estimation meta- analysis of illness progression. Schizophr.Bull., 2011, 37, 177-188.
116. Cannon, T. D.; Hennah, W.; van Erp, T. G.; Thompson, P. M.; Lonnqvist, J.; Huttunen, M.; Gasperoni, T.; Tuulio-Henriksson, A.; Pirkola, T.; Toga, A. W.; Kaprio, J.; Mazziotta, J.; Peltonen, L. Association of DISC1/TRAX haplotypes with schizophrenia, reduced prefrontal gray matter, and impaired short- and long-term memory. Arch.Gen.Psychiatry, 2005, 62, 1205-1213.
117. Arora, R. C.; Meltzer, H. Y. Serotonin2 (5-HT2) receptor binding in the frontal cortex of schizophrenic patients. J.Neural Transm.Gen.Sect., 1991, 85, 19-29.
118. Dean, B.; Hayes, W. Decreased frontal cortical serotonin2A receptors in schizophrenia. Schizophr.Res., 1996, 21, 133-139.
119. Burnet, P. W.; Eastwood, S. L.; Harrison, P. J. 5-HT1A and 5- HT2A receptor mRNAs and binding site densities are differentially altered in schizophrenia. Neuropsychopharmacology, 1996, 15, 442-455.
120. Kouzmenko, A. P.; Hayes, W. L.; Pereira, A. M.; Dean, B.; Burnet, P. W.; Harrison, P. J. 5-HT2A receptor polymorphism and steady state receptor expression in schizophrenia. Lancet, 1997, 349, 1815
121. Dean, B.; Hayes, W.; Hill, C.; Copolov, D. Decreased serotonin2A receptors in Brodmann's area 9 from schizophrenic subjects. A pathologicalorpharmacological phenomenon? Mol.Chem.Neuropathol., 1998, 34, 133-145.
122. Kouzmenko, A. P.; Scaffidi, A.; Pereira, A. M.; Hayes, W. L.; Copolov, D. L.; Dean, B. No correlation between A(-1438)G polymorphism in 5-HT2A receptor gene promoter and the density of frontal cortical 5-HT2A receptors in schizophrenia. Hum.Hered., 1999, 49, 103-105.
123. Pralong, D.; Tomaskovic-Crook, E.; Opeskin, K.; Copolov, D.; Dean, B. Serotonin(2A) receptors are reduced in the planum temporale from subjects with schizophrenia. Schizophr.Res., 2000, 44, 35-45.
124. Matsumoto, I.; Inoue, Y.; Iwazaki, T.; Pavey, G.; Dean, B. 5-HT2A and muscarinic receptors in schizophrenia: a postmortem study. Neurosci.Lett., 2005, 379, 164-168.
125. Kang, K.; Huang, X. F.; Wang, Q.; Deng, C. Decreased density of serotonin 2A receptors in the superior temporal gyrus in schizophrenia--a postmortem study. Progress in Neuro- psychopharmacology and Biological Psychiatry, 2009, 33, 867-871.
126. Dean, B.; Hayes, W.; Opeskin, K.; Naylor, L.; Pavey, G.; Hill, C.; Keks, N.; Copolov, D. L. Serotonin2 receptors and the serotonin transporter in the schizophrenic brain. Behav.Brain Res., 1996, 73, 169-175.
127. Gonzalez-Maeso, J.; Ang, R. L.; Yuen, T.; Chan, P.; Weisstaub, N. V.; Lopez-Gimenez, J. F.; Zhou, M.; Okawa, Y.; Callado, L. F.; Milligan, G.; Gingrich, J. A.; Filizola, M.; Meana, J. J.; Sealfon, S. C. Identification of a serotonin/glutamate receptor complex implicated in psychosis. Nature, 2008, 452, 93-97.
128. Dean, B.; Crossland, N.; Boer, S.; Scarr, E. Evidence for altered post-receptor modulation of the serotonin 2a receptor in schizophrenia. Schizophr.Res., 2008, 104, 185-197.
129. Joyce, J. N.; Shane, A.; Lexow, N.; Winokur, A.; Casanova, M. F.; Kleinman, J. E. Serotonin uptake sites and serotonin receptors are altered in the limbic system of schizophrenics. Neuropsychopharmacology, 1993, 8, 315-336.
130. Andree, T. H.; Mikuni, M.; Tong, C. Y.; Koenig, J. I.; Meltzer, H. Y. Differential effect of subchronic treatment with various neuroleptic agents on serotonin2 receptors in rat cerebral cortex. J.Neurochem., 1986, 46, 191-197.
131. Wilmot, C. A.; Szczepanik, A. M. Effects of acute and chronic treatments with clozapine and haloperidol on serotonin (5-HT2) and dopamine (D2) receptors in the rat brain. Brain Res., 1989, 487, 288-298.
132. O'Dell, S. J.; La Hoste, G. J.; Widmark, C. B.; Shapiro, R. M.; Potkin, S. G.; Marshall, J. F. Chronic treatment with clozapine or haloperidol differentially regulates dopamine and serotonin receptors in rat brain. Synapse, 1990, 6, 146-153.
133. Mikuni, M.; Meltzer, H. Y. Reduction of serotonin-2 receptors in rat cerebral cortex after subchronic administration of imipramine, chlorpromazine, and the combination thereof. Life Sci., 1984, 34, 87-92.
134. Burnet, P. W.; Chen, C. P.; McGowan, S.; Franklin, M.; Harrison, P. J. The effects of clozapine and haloperidol on serotonin-1A, -2A and -2C receptor gene expression and serotonin metabolism in the rat forebrain. Neuroscience, 1996, 73, 531-540.
135. Tauscher, J.; Kapur, S.; Verhoeff, N. P.; Hussey, D. F.; Daskalakis, Z. J.; Tauscher-Wisniewski, S.; Wilson, A. A.; Houle, S.; Kasper, S.; Zipursky, R. B. Brain serotonin 5-HT(1A) receptor binding in schizophrenia measured by positron emission tomography and [11C]WAY-100635. Arch.Gen.Psychiatry, 2002, 59, 514-520.
136. Bantick, R. A.; Montgomery, A. J.; Bench, C. J.; Choudhry, T.; Malek, N.; McKenna, P. J.; Quested, D. J.; Deakin, J. F.; Grasby, P. M. A positron emission tomography study of the 5-HT1A receptor in schizophrenia and during clozapine treatment. J.Psychopharmacol., 2004, 18, 346-354.
137. Frankle, W. G.; Lombardo, I.; Kegeles, L. S.; Slifstein, M.; Martin, J. H.; Huang, Y.; Hwang, D. R.; Reich, E.; Cangiano, C.; Gil, R.; Laruelle, M.; Abi-Dargham, A. Serotonin 1A receptor availability in patients with schizophrenia and schizo-affective disorder: a positron emission tomography imaging study with [11C]WAY 100635. Psychophamacology (Berlin), 2006, 189, 155-164.
138. Yasuno, F.; Suhara, T.; Ichimiya, T.; Takano, A.; Ando, T.; Okubo, Y. Decreased 5-HT1A receptor binding in amygdala of schizophrenia. Biological Psychiatry, 2004, 55, 439-444.
139. Dean, B.; Tomaskovic-Crook, E.; Opeskin, K.; Keks, N.; Copolov, D.No change in the density of the serotonin1A receptor, the serotonin4 receptor or the serotonin transporter in the dorsolateral prefrontal cortex from subjects with schizophrenia. Neurochem.Int., 1999, 34, 109-115.
140. Lopez-Figueroa, A. L.; Norton, C. S.; Lopez-Figueroa, M. O.; Armellini-Dodel, D.; Burke, S.; Akil, H.; Lopez, J. F.; Watson, S. J. Serotonin 5-HT1A, 5-HT1B, and 5-HT2A receptor mRNA expression in subjects with major depression, bipolar disorder, and schizophrenia. Biological Psychiatry, 2004, 55, 225-233.
141. Burnet, P. W.; Eastwood, S. L.; Harrison, P. J. [3H]WAY-100635 for 5-HT1A receptor autoradiography in human brain: a comparison with [3H]8-OH-DPAT and demonstration of increased binding in the frontal cortex in schizophrenia. Neurochem.Int., 1997, 30, 565-574.
142. Hashimoto, T.; Nishino, N.; Nakai, H.; Tanaka, C. Increase in serotonin 5-HT1A receptors in prefrontal and temporal cortices of brains from patients with chronic schizophrenia. Life Sci., 1991, 48, 355-363.
143. Simpson, M. D.; Lubman, D. I.; Slater, P.; Deakin, J. F. Autoradiography with [3H]8-OH-DPAT reveals increases in 5- HT(1A) receptors in ventral prefrontal cortex in schizophrenia. Biological Psychiatry, 1996, 39, 919-928.
144. Sumiyoshi, T.; Stockmeier, C. A.; Overholser, J. C.; Dilley, G. E.; Meltzer, H. Y. Serotonin1A receptors are increased in postmortem prefrontal cortex in schizophrenia. Brain Res., 1996, 708, 209-214.
145. Frankle, W. G.; Narendran, R.; Huang, Y.; Hwang, D. R.; Lombardo, I.; Cangiano, C.; Gil, R.; Laruelle, M.; Abi-Dargham, A. Serotonin transporter availability in patients with schizophrenia: a positron emission tomography imaging study with [11C]DASB. Biological Psychiatry, 2005, 57, 1510-1516.
146. Dean, B.; Opeskin, K.; Pavey, G.; Naylor, L.; Hill, C.; Keks, N.; Copolov, D. L. [3H]paroxetine binding is altered in the hippocampus but not the frontal cortex or caudate nucleus from subjects with schizophrenia. J.Neurochem., 1995, 64, 1197-1202.
147. Busatto, G. F.; Pilowsky, L. S.; Costa, D. C.; Ell, P. J.; David, A. S.; Lucey, J. V.; Kerwin, R. W. Correlation between reduced in vivo benzodiazepine receptor binding and severity of psychotic symptoms in schizophrenia. Am.J.Psychiatry, 1997, 154, 56-63.
148. Abi-Dargham, A.; Laruelle, M.; Krystal, J.; D'Souza, C.; Zoghbi, S.; Baldwin, R. M.; Seibyl, J.; Mawlawi, O.; de, E. G.; Charney, D.; Innis, R. B. No evidence of altered in vivo benzodiazepine receptor binding in schizophrenia. Neuropsychopharmacology, 1999, 20, 650-661.
149. Verhoeff, N. P.; Soares, J. C.; D'Souza, C. D.; Gil, R.; Degen, K.; Abi-Dargham, A.; Zoghbi, S. S.; Fujita, M.; Rajeevan, N.; Seibyl, J. P.; Krystal, J. H.; van Dyck, C. H.; Charney, D. S.; Innis, R. B. [123I]Iomazenil SPECT benzodiazepine receptor imaging in schizophrenia. Psychiatry Research, 1999, 91, 163-173.
150. Reynolds, G. P.; Stroud, D. Hippocampal benzodiazepine receptors in schizophrenia. J.Neural Transm.Gen.Sect., 1993, 93, 151-155.
151. Kiuchi, Y.; Kobayashi, T.; Takeuchi, J.; Shimizu, H.; Ogata, H.; Toru, M. Benzodiazepine receptors increase in post-mortem brain of chronic schizophrenics. Eur.Arch.Psychiatry Neurol.Sci., 1989, 239, 71-78.
152. Pandey, G. N.; Conley, R. R.; Pandey, S. C.; Goel, S.; Roberts, R. C.; Tamminga, C. A.; Chute, D.; Smialek, J. Benzodiazepine receptors in the post-mortem brain of suicide victims and schizophrenic subjects. Psychiatry Research, 1997, 71, 137-149.
153. Benes, F. M.; Wickramasinghe, R.; Vincent, S. L.; Khan, Y.; Todtenkopf, M. Uncoupling of GABA(A) and benzodiazepine receptor binding activity in the hippocampal formation of schizophrenic brain. Brain Res., 1997, 755, 121-129.
154. Dean, B.; Pavey, G.; McLeod, M.; Opeskin, K.; Keks, N.; Copolov, D. A change in the density of [(3)H]flumazenil, but not [(3)H]muscimol binding, in Brodmann's Area 9 from subjects with bipolar disorder. Journal of Affective Disorders, 2001, 66, 147-158.
155. Takano, A.; Arakawa, R.; Ito, H.; Tateno, A.; Takahashi, H.; Matsumoto, R.; Okubo, Y.; Suhara, T. Peripheral benzodiazepine receptors in patients with chronic schizophrenia: a PET study with [11C]DAA1106. Int.J.Neuropsychopharmacol., 2010, 13, 943-950.
156. Doorduin, J.; de Vries, E. F.; Willemsen, A. T.; de Groot, J. C.; Dierckx, R. A.; Klein, H. C. Neuroinflammation in schizophrenia- related psychosis: a PET study. J.Nucl.Med., 2009, 50, 1801-1807.
157. Kurumaji, A.; Wakai, T.; Toru, M. Decreases in peripheral-type benzodiazepine receptors in postmortem brains of chronic schizophrenics. J.Neural Transm., 1997, 104, 1361-1370.
158. Raghavendra Rao, V. L.; Dogan, A.; Bowen, K. K.; Dempsey, R. J. Traumatic brain injury leads to increased expression of peripheral- type benzodiazepine receptors, neuronal death, and activation of astrocytes and microglia in rat thalamus. Exp.Neurol., 2000, 161, 102-114.
159. Bressan, R. A.; Erlandsson, K.; Mulligan, R. S.; Gunn, R. N.; Cunningham, V. J.; Owens, J.; Ell, P. J.; Pilowsky, L. S. Evaluation of NMDA receptors in vivo in schizophrenic patients with [123I]CNS 1261 and SPET: preliminary findings. Ann.N.Y.Acad.Sci., 2003, 1003, 364-367.
160. Pilowsky, L. S.; Bressan, R. A.; Stone, J. M.; Erlandsson, K.; Mulligan, R. S.; Krystal, J. H.; Ell, P. J. First in vivo evidence of an NMDA receptor deficit in medication-free schizophrenic patients. Mol.Psychiatry, 2006, 11, 118-119.
161. Beneyto, M.; Kristiansen, L. V.; Oni-Orisan, A.; McCullumsmith, R. E.; Meador-Woodruff, J. H. Abnormal glutamate receptor expression in the medial temporal lobe in schizophrenia and mood disorders. Neuropsychopharmacology, 2007, 32, 1888-1902.
162. Kerwin, R.; Patel, S.; Meldrum, B. Quantitative autoradiographic analysis of glutamate binding sites in the hippocampal formation in normal and schizophrenic brain post mortem. Neuroscience, 1990, 39, 25-32.
163. Gao, X. M.; Sakai, K.; Roberts, R. C.; Conley, R. R.; Dean, B.; Tamminga, C. A. Ionotropic glutamate receptors and expression of N-methyl-D-aspartate receptor subunits in subregions of human hippocampus: effects of schizophrenia. Am.J.Psychiatry, 2000, 157, 1141-1149.
164. Toro, C.; Deakin, J. F. NMDA receptor subunit NRI and postsynaptic protein PSD-95 in hippocampus and orbitofrontal cortex in schizophrenia and mood disorder. Schizophr.Res., 2005, 80, 323-330.
165. Meador-Woodruff, J. H.; Healy, D. J. Glutamate receptor expression in schizophrenic brain. Brain Res.Brain Res.Rev., 2000, 31, 288-294.
166. Noga, J. T.; Hyde, T. M.; Herman, M. M.; Spurney, C. F.; Bigelow, L. B.; Weinberger, D. R.; Kleinman, J. E. Glutamate receptors in the postmortem striatum of schizophrenic, suicide, and control brains. Synapse, 1997, 27, 168-176.
167. Clinton, S. M.; Meador-Woodruff, J. H. Abnormalities of the NMDA Receptor and Associated Intracellular Molecules in the Thalamus in Schizophrenia and Bipolar Disorder. Neuropsychopharmacology, 2004, 29, 1353-1362.
168. Dracheva, S.; Byne, W.; Chin, B.; Haroutunian, V. Ionotropic glutamate receptor mRNA expression in the human thalamus: absence of change in schizophrenia. Brain Res., 2008, 1214, 23-34.
169. Ibrahim, H. M.; Hogg, A. J., Jr.; Healy, D. J.; Haroutunian, V.; Davis, K. L.; Meador-Woodruff, J. H. Ionotropic glutamate receptor binding and subunit mRNA expression in thalamic nuclei in schizophrenia. Am.J.Psychiatry, 2000, 157, 1811-1823.
170. Raedler, T. J.; Knable, M. B.; Jones, D. W.; Urbina, R. A.; Gorey, J. G.; Lee, K. S.; Egan, M. F.; Coppola, R.; Weinberger, D. R. In vivo determination of muscarinic acetylcholine receptor availability in schizophrenia. Am.J.Psychiatry, 2003, 160, 118-127.
171. Dean, B.; Crook, J. M.; Opeskin, K.; Hill, C.; Keks, N.; Copolov, D. L. The density of muscarinic M1 receptors is decreased in the caudate-putamen of subjects with schizophrenia. Mol.Psychiatry, 1996, 1, 54-58.
172. Crook, J. M.; Dean, B.; Pavey, G.; Copolov, D. The binding of [3H]AF-DX 384 is reduced in the caudate-putamen of subjects with schizophrenia. Life Sci., 1999, 64, 1761-1771.
173. Crook, J. M.; Tomaskovic-Crook, E.; Copolov, D. L.; Dean, B. Decreased muscarinic receptor binding in subjects with schizophrenia: a study of the human hippocampal formation. Biological Psychiatry, 2000, 48, 381-388.
174. Crook, J. M.; Tomaskovic-Crook, E.; Copolov, D. L.; Dean, B. Low muscarinic receptor binding in prefrontal cortex from subjects with schizophrenia: a study of Brodmann's areas 8, 9, 10, and 46 and the effects of neuroleptic drug treatment. Am.J.Psychiatry, 2001, 158, 918-925.
175. Dean, B.; McLeod, M.; Keriakous, D.; McKenzie, J.; Scarr, E. Decreased muscarinic(1) receptors in the dorsolateral prefrontal cortex of subjects with schizophrenia. Mol.Psychiatry, 2002, 7, 1083-1091.
176. Mancama, D.; Arranz, M. J.; Landau, S.; Kerwin, R. Reduced expression of the muscarinic 1 receptor cortical subtype in schizophrenia. Am.J.Med.Genet.B Neuropsychiatr.Genet., 2003, 119, 2-6.
177. Zavitsanou, K.; Katsifis, A.; Filomena, M.; Xu-Feng, H. Investigation of M1/M4 muscarinic receptors in the anterior cingulate cortex in schizophrenia, bipolar disorder, and major depression disorder. Neuropsychopharmacology, 2004, 29, 619-625.
178. Deng, C.; Huang, X. F. Decreased density of muscarinic receptors in the superior temporal gyrus in schizophrenia. J.Neurosci.Res., 2005, 81, 883-890.
179. Scarr, E.; Sundram, S.; Keriakous, D.; Dean, B. Altered hippocampal muscarinic m4, but not m1, receptor expression from subjects with schizophrenia. Biological Psychiatry, 2007, 61, 1161-1170.
180. Newell, K. A.; Zavitsanou, K.; Jew, S. K.; Huang, X. F. Alterations of muscarinic and GABA receptor binding in the posterior cingulate cortex in schizophrenia. Progress in Neuro- psychopharmacology and Biological Psychiatry, 2007, 31, 225-233.
181. Scarr, E.; Cowie, T. F.; Kanellakis, S.; Sundram, S.; Pantelis, C.; Dean, B. Decreased cortical muscarinic receptors define a subgroup of subjects with schizophrenia. Mol Psychiatry, 2009, 14, 1017-1023.
182. Salah-Uddin, H.; Scarr, E.; Pavey, G.; Harris, K.; Hagan, J. J.; Dean, B.; Challiss, R. A.; Watson, J. M. Altered M(1) muscarinic acetylcholine receptor (CHRM1)-Galpha(q/11) coupling in a schizophrenia endophenotype. Neuropsychopharmacology, 2009, 34, 2156-2166.
183. Gibbons, A. S.; Scarr, E.; Boer, S.; Money, T.; Jeon, W. J.; Felder, C.; Dean, B. Widespread decreases in cortical muscarinic receptors in a subset of people with schizophrenia. Int.J.Neuropsychopharmacol., 2012, 1-10.
184. Scarr, E.; Keriakous, D.; Crossland, N.; Dean, B. No change in cortical muscarinic M2, M3 receptors or [35S]GTPgammaS binding in schizophrenia. Life Sci., 2006, 78, 1231-1237.
185. Dean, B.; Crook, J. M.; Pavey, G.; Opeskin, K.; Copolov, D. L. Muscarinic1 and 2 receptor mRNA in the human caudate-putamen: no change in m1 mRNA in schizophrenia. Mol.Psychiatry, 2000, 5, 203-207.
186. Dean, B.; Gray, L.; Keriakous, D.; Scarr, E. A comparison of M1 and M4 muscarinic receptors in the thalamus from control subjects and subjects with schizophrenia. Thalamus and Related Systems, 2004, 2, 287-295.
187. Wong, D. F.; Kuwabara, H.; Horti, A. G.; Raymont, V.; Brasic, J.; Guevara, M.; Ye, W.; Dannals, R. F.; Ravert, H. T.; Nandi, A.; Rahmim, A.; Ming, J. E.; Grachev, I.; Roy, C.; Cascella, N. Quantification of cerebral cannabinoid receptors subtype 1 (CB1) in healthy subjects and schizophrenia by the novel PET radioligand [11C]OMAR. Neuroimage., 2010, 52, 1505-1513.
188. Dean, B.; Sundram, S.; Bradbury, R.; Scarr, E.; Copolov, D. Studies on [3H]CP-55940 binding in the human central nervous system: regional specific changes in density of cannabinoid-1 receptors associated with schizophrenia and cannabis use. Neuroscience, 2001, 103, 9-15.
189. Zavitsanou, K.; Garrick, T.; Huang, X. F. Selective antagonist [3H]SR141716A binding to cannabinoid CB1 receptors is increased in the anterior cingulate cortex in schizophrenia. Progress in Neuro-psychopharmacology and Biological Psychiatry, 2004, 28, 355-360.
190. Deng, C.; Han, M.; Huang, X. F. No changes in densities of cannabinoid receptors in the superior temporal gyrus in schizophrenia. Neurosci.Bull., 2007, 23, 341-347.
191. Eggan, S. M.; Hashimoto, T.; Lewis, D. A. Reduced cortical cannabinoid 1 receptor messenger RNA and protein expression in schizophrenia. Arch.Gen.Psychiatry, 2008, 65, 772-784.
192. Johns, A. Psychiatric effects of cannabis. Br.J.Psychiatry, 2001, 178, 116-122.
193. Iwabuchi, K.; Ito, C.; Tashiro, M.; Kato, M.; Kano, M.; Itoh, M.; Iwata, R.; Matsuoka, H.; Sato, M.; Yanai, K. Histamine H1 receptors in schizophrenic patients measured by positron emission tomography. European Neuropsychopharmacology, 2005, 15, 185-191.
194. Nakai, T.; Kitamura, N.; Hashimoto, T.; Kajimoto, Y.; Nishino, N.; Mita, T.; Tanaka, C. Decreased histamine H1 receptors in the frontal cortex of brains from patients with chronic schizophrenia. Biological Psychiatry, 1991, 30, 349-356.
195. Tamminga, C. A. Accelerating new knowledge in schizophrenia. Am.J.Psychiatry, 2008, 165, 949-951.
196. Martinot, J. L.; Peron-Magnan, P.; Huret, J. D.; Mazoyer, B.; Baron, J. C.; Boulenger, J. P.; Loc'h, C.; Maziere, B.; Caillard, V.; Loo, H. Striatal D2 dopaminergic receptors assessed with positron emission tomography and [76Br]bromospiperone in untreated schizophrenic patients. Am.J.Psychiatry, 1990, 147, 44-50.
197. Schmitt, G. J.; Meisenzahl, E. M.; Frodl, T.; La, F. C.; Hahn, K.; Moller, H. J.; Dresel, S. Increase of striatal dopamine transmission in first episode drug-naive schizophrenic patients as demonstrated by [(123)I]IBZM SPECT. Psychiatry Research, 2009, 173, 183-189.
198. Hirvonen, J.; van Erp, T. G.; Huttunen, J.; Aalto, S.; Nagren, K.; Huttunen, M.; Lonnqvist, J.; Kaprio, J.; Cannon, T. D.; Hiet-aletal/et-ala, J. Brain dopamine d1 receptors in twins discordant for schizophrenia. Am.J.Psychiatry, 2006, 163, 1747-1753.
199. Asai, Y.; Takano, A.; Ito, H.; Okubo, Y.; Matsuura, M.; Otsuka, A.; Takahashi, H.; Ando, T.; Ito, S.; Arakawa, R.; Asai, K.; Suhara, T. GABAA/Benzodiazepine receptor binding in patients with schizophrenia using [11C]Ro15-4513, a radioligand with relatively high affinity for alpha5 subunit. Schizophr.Res., 2008, 99, 333-340.